Navigation Links
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
Date:11/3/2008

ward to further evaluating the correlation between rash and clinical activity, as well as alternate dosing schedules of CR011-vcMMAE," commented Dr. Hwu.

CuraGen is currently enrolling patients into a Phase I portion of this trial to evaluate more frequent dosing schedules of CR011-vcMMAE, including a weekly and a two out of every three-week regimen, to explore if more frequent administration can provide additional activity in patients with metastatic melanoma. CR011-vcMMAE is also being studied in an ongoing Phase II trial in patients with metastatic breast cancer who have received previous chemotherapy. CuraGen anticipates providing updated data from the ongoing melanoma and breast cancer studies in the first half of 2009.

"While we continue to finalize data from this study, develop data from more frequent dosing in patients with metastatic melanoma and from the Phase II study in patients with breast cancer, we will be engaging in discussions with potential partners as we develop plans for the advanced stages of development," added Dr. Shannon. "The goal of a partnership will be to support the financial, development and commercial resources that will be required in advanced development, improving the risk profile to CuraGen shareholders while maintaining upside potential."

In addition to M. D. Anderson, other sites participating in the melanoma trial include Yale Cancer Center, New Haven, CT; The Angeles Clinic and Research Institute, Santa Monica, CA; and New York University Medical Center, New York, NY.

Reprints of the presentation will be made available on CuraGen's website at http://www.curagen.com or can be requested by emailing info@curagen.com.

Conference Call Details and Dial-in Information

Date: Monday, November 3, 2008

Time: 11:00 a.m. EDT

Dial-in: 877-272-5391 (domestic)

706-758-4315 (international)

Passcode: 71190
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014 Clementia Pharmaceuticals, ... Agency (EMA) has granted Orphan Medicinal Product ... candidate, for the treatment of fibrodysplasia ossificans ... disabling genetic disease characterized by painful, recurrent ... new abnormal bone formation. This process, known ...
(Date:11/21/2014)... Ontario , Nov. 20, 2014  RedRick ... mounting solutions and reading room environment guidance, has ... newest musculoskeletal radiology reading room, which may also ... designs at Penn Medicine. "In ... the American College of Radiology,s Imaging 3.0 ™ ...
(Date:11/21/2014)...   Coqui RadioPharmaceuticals Corp. , a medical isotope ... of Molybdenum-99 (Mo-99), is proud to announce it has ... design its Medical Isotope Production Facility (MIPF) in ... isotope of Technetium-99, which is used in 80 percent ... legislation making it a national priority to produce Mo-99, ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... Del., May 14, 2012  Synchrogenix Information Strategies Inc., a ... to announce the addition of a new office in ... Synchrogenix CEO, Ellen Barrosse, has appointed Bengt Olsson ... company,s newest office, located in Stockholm, Sweden.  With more ...
... 14, 2012  Eli Lilly and Company (NYSE: LLY ... its clinical oncology pipeline during the 48th Annual Meeting of ... Ill. from June 1 – 5, 2012. ... late-stage development to treat various types of cancer. The company ...
Cached Medicine Technology:Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 2Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 3Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 4
(Date:11/23/2014)... has recently announced that its Special Friday Shoes sales, ... offer will provide ladies many gorgeous shoes at greatly discounted ... women’s dresses retailers, and its shoes include many models in ... that day: Everything at Tbdress.com is up to 90% off. ... People can use the following coupon codes as well: , ...
(Date:11/23/2014)... 21, 2014 (HealthDay News) -- Close friends have more ... group does, a new study says. "We,ve ... have an influence on individual alcohol use, but there ... peer group and the friend group,s influence on those ... School of Public Health, said in a university news ...
(Date:11/23/2014)... This evaluation provides a basic conclusion ... and manufacturing technological innovation. Then, the evaluation investigates ... in information. In this part, the evaluation provides ... and 2009-2014 market shares for each company. Through ... and Chinese suppliers finish market of Femoral Occurs ...
(Date:11/23/2014)... 23, 2014 More than two dozen ... a federal litigation involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), ... Liebhard LLP reports. , A Case List updated ... class of Type 2 diabetes medications referred to as ... District Court, Southern District of California, where a federal ...
(Date:11/23/2014)... DC (PRWEB) November 23, 2014 “BlackVue” ... Tech Report , which features the latest and ... technology expert and reporter for NewsWatch, conducted the product ... are unique and powerful options in the car camera ... rising and it can be hard to find the ...
Breaking Medicine News(10 mins):Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Close Friends May Be Key to Teens' Drinking 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2
... The distinctive ability of mothers to identify the cries ... is critical to the survival of these offspring. In ... to recognize and respond to the smiles and cries of ... and social development of these babies. We have had ...
... Tips for using the full line of dermatologist ... The Theraplex Company, the,makers of a full line ... range of dry skin conditions, is launching its ... and advice for,healthy looking and beautiful skin. Four ...
... Schizophrenia emerges from an altered pattern of brain development, ... cause the brain to develop along a path that ... article to be published in Biological Psychiatry on March ... link to schizophrenia. , A prior genetic mapping study ...
... TotalLook MammoAdvantage(TM)Provides Enhanced Image Quality, Customization ... and Workflow Benefits to Mammography ... Inc. (Nasdaq:,ICAD), an industry-leading provider of Computer-Aided Detection ... announced the,availability of the TotalLook MammoAdvantage system which ...
... can used to diagnose severity of bipolar illness , , ... blood associated with mood disorders have been identified by ... finding may change the way bipolar illness is diagnosed ... 96 patients and found varying levels of the biomarkers ...
... renters told Apartments.com, during national heart, awareness month, ... of on-site fitness facilities offered ... The majority of renters lead a healthy,lifestyle by eating ... would also,prefer to step up their current workout routine ...
Cached Medicine News:Health News:Maternal love: How a mother's brain responds to her infant 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 4Health News:New genetic association with schizophrenia found by researchers 2Health News:iCAD Introduces Next-Generation TotalLook Film Digitizer 2Health News:iCAD Introduces Next-Generation TotalLook Film Digitizer 3Health News:Biomarkers for Mood May Alter Psychiatric Treatments 2Health News:National Survey Reveals Most Renters Want What They Do Not Have: On-Site Workout Facilities 2
... II Smart ValveTM, Hakim, H-V ... intelligent choice for meeting the ... Automatic pressure response causes the ... the conditions present, eliminating the ...
Codman Hakim Programmable valve cylindrical offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition will often change over t...
Leadpoint Micro-Electrode Recording...
... Using advanced 3D matching algorithms developed ... Stealthmerge automatically merges image sets from a ... and PET, regardless of acquisition orientation. Stealthmerge ... eliminating the requirement to scan tissue outside ...
Medicine Products: